Pregnancy Rates in IVF After Ovulation Triggering With Recombinant or Urinary Human Chorionic Gonadotrophin (HCG)
Phase 3
- Conditions
- Embryonic DevelopmentPregnancyVEGF
- Interventions
- Drug: 10000 IU urinary HCGDrug: 250 mcg recombinant HCG
- Registration Number
- NCT00954265
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Brief Summary
To access whether the ovulation triggering with rec-HCG instead urinary-HCG has any impact on the blastulation rate and pregnancy rate of patients undergoing IVF treatment
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 130
Inclusion Criteria
- FSH<12,
- normal sperm,less than 36y,
- single blastocyst transfer
Exclusion Criteria
- endometriosis stage 3&4,
- pco
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Urinary-HCG group 10000 IU urinary HCG These patients received u-HCG for ovulation triggering during ovarian stimulation for IVF Recombinant HCG group 250 mcg recombinant HCG These patients received rec-HCG for ovulation triggering during ovarian stimulation for IVF
- Primary Outcome Measures
Name Time Method blastulation rate on day-5
- Secondary Outcome Measures
Name Time Method pregnancy rates, VEGF levels, OHSS rate 14 days after oocyte pick up
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of rec-HCG influence blastulation and pregnancy rates compared to urinary-HCG in IVF?
How does recombinant HCG compare to urinary HCG in terms of efficacy and safety for ovulation triggering in IVF?
Are there specific biomarkers that predict response to rec-HCG versus urinary-HCG in IVF cycles?
What adverse events are associated with rec-HCG use in IVF and how are they managed compared to urinary-HCG?
What are the current trends in HCG alternatives for ovulation triggering in IVF and how does rec-HCG fit within this landscape?
Trial Locations
- Locations (1)
Centre for Reproductive Medicine, UZ Brussel
🇧🇪Brussels, Jette, Belgium
Centre for Reproductive Medicine, UZ Brussel🇧🇪Brussels, Jette, Belgium